Nanotechnology Perceptions
ISSN 1660-6795
www.nano-ntp.com

Use of Liposomal Curcumin for Oral Cancer Treatment: A Systematic Review and Meta Analysis

Nitin Bhagat[1], Sajjad Salam[2], Abhinav Garg[3], Vijayanandhan Venkatesan[4], Shetty Hardik[5], Gaganashree H G[6], Sumana Kumar[7], Ritik Kashwani[8]

[1]Professor, School of Dental Sciences, Manav Rachna International University of Research and Studies, India, nitinbhagat.sds@mrei.ac.in
[2]FFDRCS (Ire) MFDRCS (Ire) MDS, Dental and Maxillofacial Services, Bahrain Defense Force Hospital, Bahrain Defense Forces - Military Hospital, drsajjadsalam@gmail.com
[3]Reader, Department of Oral and Maxillofacial Surgery, Luxmi Bai Institute of Dental Sciences & Hospital, India, garg.abhinav04@gmail.com
[4]Faculty of Pharmacognosy, JKKN College of Pharmacy, JKKN Educational Institutions, Kumarapalayam, Namakkal, India, vijayanandhanvenkatesh@gmail.com
[5]Reader, VananChal Dental College, Jharkhand, India, drhardikshetty@gmail.com
[6]MDS, Oral and Maxillofacial Surgery , College of Dental Science, Davanagere, India, gaganashree1597@gmail.com
[7]Associate Professor, Department of Microbiology, JSS Academy of Higher Education & Research, Sri Shivarathreeshwara Nagar, India, sumana.k@jssuni.edu.in
[8]BDS, Private Practitioner, Ex-Junior Resident, School of Dental Sciences, Sharda University, Greater Noida, India, docritikkashwani@yahoo.com

Background: Oral cancer is a significant health concern with limited effective treatment options. Curcumin, a compound found in turmeric, has shown promise in cancer therapy due to its anti-inflammatory and anticancer properties. Liposomal curcumin enhances the bioavailability and efficacy of curcumin. This systematic review and meta-analysis aim to evaluate the effectiveness of liposomal curcumin in treating oral cancer. Objectives: To assess the efficacy and safety of liposomal curcumin as a therapeutic agent for oral cancer through a comprehensive review and meta-analysis of existing studies. Methods: A systematic search was conducted in major databases including PubMed, Scopus, and Web of Science for studies published up to Dec 2023. Criteria for inclusion involved clinical trials, case studies, and observational studies assessing the use of liposomal curcumin in oral cancer treatment. Data on treatment outcomes, adverse effects, and overall efficacy were extracted and analyzed. Statistical analysis was performed using meta-analysis tools to determine the pooled effect size. Results: Liposomal curcumin significantly improved bioavailability and exhibited notable anti-tumor effects, including apoptosis induction and proliferation suppression, in preclinical studies. Despite limited clinical trials specific to oral cancer, ongoing research suggests its potential for enhancing treatment outcomes. Conclusion:

Liposomal curcumin appears to be an effective adjunctive treatment for oral cancer, offering potential benefits in enhancing therapeutic outcomes and reducing adverse effects. Further research with larger sample sizes and longer follow-up periods is recommended to confirm these findings and establish optimal dosing protocols.

Keywords: Cancer Therapy Curcumin, Drug delivery, Natural Compound, Liposomes, Oral cancer.

1. Introduction

Oral cancer is a major public health concern, ranking as the sixth most frequent disease worldwide [1]. Despite advances in traditional treatments such as surgery, radiotherapy, and chemotherapy, the prognosis for many patients remains dismal, especially in advanced stages [2]. This ongoing dilemma highlights the crucial need for novel therapeutic techniques to improve treatment outcomes and patient quality of life. Natural chemicals have recently received increased attention in cancer research due to their putative therapeutic capabilities and typically favorable toxicity profiles [3]. Curcumin, the primary curcuminoid found in turmeric (Curcuma longa), has emerged as a promising cancer treatment option, particularly oral cancer [4].

Numerous biological actions, including anti-inflammatory, antioxidant, and anti-proliferative qualities, have been shown for curcumin [5]. These characteristics make it more intriguing when considering oral cancer, as oxidative stress and chronic inflammation are major contributors to carcinogenesis [6]. Curcumin's poor bioavailability when taken orally, mainly because of its low water solubility, fast metabolism, and restricted absorption, has hampered its therapeutic applicability [7]. Liposomal technology offers a possible way around these restrictions. Liposomes are phospholipid bilayer-based tiny vesicles that have the ability to enclose both hydrophilic and hydrophobic substances [8]. Curcumin can be better absorbed by cells, made more soluble, and shielded from fast metabolism by encapsulating it in liposomes [9].

The goal of this study is to present a thorough examination of the state of the research on liposomal curcumin's application to the treatment of oral cancer. We'll look at the prevalence of oral cancer, curcumin's modes of action, the benefits of liposomal delivery methods, preclinical research, recent clinical research, possible uses, difficulties, and future directions in this area.

Malignancies of the lip, oral cavity, and oropharynx collectively referred to as oral cancer constitute a substantial worldwide health burden. Around 377,713 new instances of lip and oral cavity cancer were estimated globally in 2020 by the Global Cancer Observatory (GLOBOCAN), making up 2% of all cancer cases [10]. Geographically, there are large regional variations in the incidence rates; South Asian nations, especially India, have the highest rates, with oral cancer being the most frequent cancer among men there [11].

2. Materials and Methodology

A comprehensive literature review & meta analysis was conducted to gather existing research on liposomal curcumin and its potential for oral cancer treatment. This included :

Search Strategy

A comprehensive literature search was conducted across multiple databases including PubMed, Scopus, Web of Science, and Google Scholar. The search terms used included "curcumin," "turmeric," "Curcuma longa," "cancer," "head and neck squamous cell carcinoma," "HNSCC," "bioavailability," "anti-inflammatory," "antioxidant," and "therapeutic effects." The search was limited to articles published in English between 2000 and 2024. Reference lists of relevant articles were also screened for additional studies.

Eligibility Criteria

Studies were included in the review if they met the following criteria:

1. Focused on the therapeutic effects of curcumin.
2. Investigated curcumin's impact on cancer, particularly head and neck squamous cell carcinoma (HNSCC).
3. Provided detailed methodology and results.
4. Published in peer-reviewed journals.
5. Included both in vitro and in vivo studies, as well as clinical trials.

Exclusion criteria were:

1. Articles not in English.
2. Studies lacking sufficient methodological detail.
3. Reviews, editorials, and opinion pieces without original data.

Study Selection

The initial search yielded 280 articles. After removing duplicates, titles and abstracts of the remaining 180 articles were screened for relevance. Full texts of 70 potentially relevant articles were retrieved and assessed for eligibility based on the predefined criteria. Ultimately, 40 studies were included in the review.

Data Extraction

Data were extracted from the included studies using a standardized extraction form. The following information was recorded for each study:

- Authors and publication year
- Study design (in vitro, in vivo, clinical trial)
- Cancer type
- Main findings related to curcumin’s therapeutic effects

- Mechanisms of action
- Bioavailability strategies
- Combination with other treatments

Two reviewers independently extracted the data, and discrepancies were resolved by consensus. The extracted data were then synthesized to provide a comprehensive overview of the therapeutic potential of curcumin, particularly in the context of head and neck squamous cell carcinoma.

Statistical Analysis

All the data was tabulated in excel format and conclusions were drawn using SPSS software. (IBM SPSS Version 28.0)

PRISMA FLOWCHART OF THE STUDY IS SHOWN IN Figure 1



REVIEW

Several risk factors contribute to the development of oral cancer:

Tobacco and Alcohol Use

Tobacco use, including smoking and smokeless tobacco products, is the most significant risk factor for oral cancer. It is estimated that about 80% of oral cancer cases are attributable to

tobacco use [12]. Alcohol consumption, particularly when combined with tobacco use, significantly increases the risk of oral cancer. The synergistic effect of tobacco and alcohol can increase the risk by more than 35 times compared to non-users [13]

Human Papillomavirus (HPV) Infection

HPV infection is becoming more widely acknowledged as a risk factor for oropharyngeal malignancies, especially with high-risk strains like HPV-16 and HPV-18. Recent years have shown an increase in the incidence of HPV-positive oropharyngeal malignancies, particularly in younger populations in developed nations [14].

Chronic Irritation and Inflammation

Oral cancer risk may rise with chronic irritation of the oral mucosa caused by sharp teeth, ill-fitting dentures, or other physical damage. Oral submucous fibrosis, a chronic inflammatory condition that is linked to an increased risk of oral cancer, is particularly widespread in South Asian communities as a result of betel quid chewing [15].

Diet and Nutrition

Oral cancer risk has been linked to a diet high in processed foods and low in fruits and vegetables. On the other hand, a diet high in micronutrients and antioxidants might be protective [16].

Genetic Factors

Oral cancer risk is raised by several hereditary disorders, including dyskeratosis congenita and Fanconi anemia. Furthermore, a person's vulnerability to oral cancer may be influenced by genetic variations in enzymes involved in the metabolism of carcinogens [17].

Comprehending these risk factors is crucial in formulating efficacious preventative measures and pinpointing high-risk demographics who could potentially profit from focused interventions or screening initiatives. The need for multi-modal therapeutic methods, such as innovative medicines like liposomal curcumin, which may address various aspects of cancer formation and progression, is further highlighted by the multifactorial nature of the etiology of oral cancer.

CURCUMIN : MECHANISM OF ACTION IN ORAL CANCER

For ages, curcumin, also known as diferuloylmethane, has been utilized in traditional medicine [18]. Recent decades have seen a significant amount of research into its potential as an anti-cancer agent, which has revealed a wide range of intricate mechanisms by which it works. The main pathways through which curcumin may affect the onset and spread of oral cancer will be discussed in this section.

Anti-inflammatory Effects

One known risk factor for oral cancer is chronic inflammation [19]. Curcumin modulates multiple molecular targets to demonstrate powerful anti-inflammatory effects. Nuclear factor-kappa B (NF-κB), a crucial transcription factor implicated in inflammatory responses and carcinogenesis, is inhibited by curcumin, as multiple studies have shown [20]. Furthermore, it has been demonstrated that curcumin inhibits the expression of pro-inflammatory cytokines

such interleukin-1β (IL-1β), IL-6 (IL-6), and tumor necrosis factor-α (TNF-α) [21].

Antioxidant Activity

The development and spread of oral cancer are significantly influenced by oxidative stress [22]. Strong antioxidants including glutathione peroxidase, catalase, and superoxide dismutase are all activated by curcumin, which also scavenges free radicals [23]. Curcumin may be able to stop the oxidative damage that cells cause to their DNA, therefore preventing the mutations that cause cancer. Curcumin dramatically lowered oxidative stress markers in individuals with oral leukoplakia, a precancerous disease, according to a research by Krishnaswamy et al. [24].

Modulation of Cell Signaling Pathways

Curcumin interacts with many signaling molecules in cells that are implicated in the development of cancer. It has been demonstrated to prevent the activation of several growth factor receptors, protein kinases, and transcription factors that support the survival and growth of cancer cells [25]. Important routes impacted by curcumin consist of:

- NF-κB pathway: Apart from its function in inflammation, NF-κB controls genes related to metastasis, proliferation, and cell survival [26].

- STAT3 pathway: Oral cancer cells frequently exhibit constitutive activation of the signal transducer and activator of transcription 3 (STAT3), which facilitates the cells' survival and growth [27].

- MAPK pathway: Cell survival, proliferation, and differentiation are all impacted by the mitogen-activated protein kinase (MAPK) pathway [28].

Through modification of these signaling pathways, curcumin suppressed the proliferation and invasion of head and neck squamous cell carcinoma cells, as indicated by a study by Wilken et al. [29].

Induction of Apoptosis

The capacity of cancer cells to resist apoptosis, or programmed cell death, is one of their defining characteristics. Curcumin has proven to be able to cause apoptosis in a number of oral cancer cell lines via a variety of methods [30]:

Caspases, which are essential for carrying out apoptosis, are activated. Bcl-2 family proteins are modified, changing the ratio of pro- to anti-apoptotic members.

- Induction of mitochondrial malfunction, which triggers the apoptotic cascade and releases cytochrome c.

Curcumin triggered apoptosis in human oral cancer cells via a p53-dependent mechanism, according to a study by Chakravarti et al. [31].

Inhibition of Angiogenesis

Tumors require angiogenesis—the development of new blood vessels—in order to grow larger than a specific size. Curcumin has demonstrated anti-angiogenic characteristics [32]:

Repressing the migration and proliferation of endothelial cells - Downregulating pro-angiogenic proteins such as vascular endothelial growth factor (VEGF) - Blocking matrix

metalloproteinases (MMPs) involved in the extracellular matrix remodeling during angiogenesis

Curcumin suppressed angiogenesis in oral squamous cell carcinoma by downregulating the production of VEGF, as observed by Lin et al. [33].

Epigenetic Modulation

Tumors require angiogenesis—the development of new blood vessels—in order to grow larger than a specific size. Curcumin has demonstrated anti-angiogenic characteristics [32]:

Recent research indicates that curcumin may use epigenetic modification to carry out its anti-cancer properties. It has been demonstrated that curcumin inhibits histone deacetylases (HDACs) and DNA methyltransferases (DNMTs), possibly restoring abnormal epigenetic modifications linked to the development of cancer [34]. The suppression of oncogenes and the reexpression of tumor suppressor genes may be facilitated by this epigenetic modification.

Immunomodulation

Immunomodulatory actions of curcumin have been shown, which may explain some of its anti-cancer effects. It has been demonstrated to boost T cell differentiation, increase the activity of natural killer (NK) cells, and regulate the synthesis of cytokines important in anti-tumor immune responses [35]. The immune evasion strategies used by cancer cells may be circumvented with the aid of these immunomodulatory actions.

Inhibition of Cancer Stem Cells

It is believed that cancer stem cells (CSCs) are essential for the development, spread, and recurrence of tumors. Curcumin may target CSCs in a variety of cancer types, including oral cancer, according to recent studies [36]. It has been demonstrated that curcumin inhibits CSCs' ability to self-renew and modifies important signaling pathways, including the Notch and Wnt/β-catenin pathways, that are crucial in CSC maintenance.

Curcumin is a promising option for the treatment of oral cancer because of its various modes of action. However, its therapeutic usefulness has been limited due to its poor oral bioavailability. We will look at how liposomal technology might be able to help with this problem in the section that follows.

Liposomal Technology: Enhancing Curcumin Delivery

Due to its poor oral absorption, curcumin's therapeutic potential in the treatment of oral cancer is severely limited. Its limited water solubility, quick metabolism, and inadequate absorption in the gastrointestinal system are the main causes of its low bioavailability [37]. Liposomal technology has become a viable means of getting around these restrictions and improving curcumin's transport and effectiveness.

Liposome Structure and Properties

Liposomes are minuscule vesicles that consist of an aqueous core surrounded by one or more phospholipid bilayers. Liposomes are ideal carriers for a wide range of therapeutic treatments because of their unusual structure, which enables them to encapsulate both hydrophilic and hydrophobic molecules [38]. Liposomes have several key characteristics that make them

appealing for medication delivery, such as:

Biocompatibility: Since phospholipids used to make liposomes are identical to those in cell membranes, there is a lower chance of toxicity or immunological reactions.

Enhanced drug solubility: Liposomes can improve the solubility of weakly soluble substances like curcumin in aqueous settings by encasing them.

Protection from degradation: The medicine enclosed in the lipid bilayer is protected from the body's various degradative processes, including enzymatic breakdown.

Targeted delivery: By modifying liposomes to target particular tissues or cell types, it may be possible to increase the concentration of the medication at the intended site of action.

Controlled release: The drug encapsulation can be made to release from the lipid bilayer at a predetermined rate or in response to certain stimuli

Advantages of Liposomal Curcumin

Encapsulating curcumin in liposomes offers several advantages that address the limitations of free curcumin:

Enhanced Bioavailability

The following benefits of encapsulating curcumin in liposomes mitigate the drawbacks of free curcumin:

Improved Absorbance

Curcumin's bioavailability is greatly increased via liposomal encapsulation. When compared to traditional curcumin formulations, studies have shown bioavailability improvements of up to 20 times [39]. The reasons for this increased bioavailability are:

- Increased solubility: Curcumin is more soluble in aqueous media because liposomes give it a hydrophobic environment within their lipid bilayers.

- Protection against metabolism: Curcumin's half-life in the body may be extended by the liposomal barrier, which prevents it from being rapidly metabolized in the liver and intestinal wall.

- Enhanced absorption: By means of endocytosis or fusing with cell membranes, liposomes may be able to improve the absorption of curcumin via the intestinal epithelium

Enhanced Stability

Curcumin is susceptible to changes in pH, heat, light, and other environmental conditions. The protective environment that liposomal encapsulation offers enhances curcumin's stability in a range of situations. Improved shelf life and preservation of therapeutic efficacy after administration and storage may result from this increased stability.

Delivery with Specificity

Curcumin concentration at the intended location of action may be increased by tailoring liposomes to target particular tissues or cell types. There are several ways to accomplish this focused delivery:

Passive targeting: Due to leaky vasculature and inadequate lymphatic drainage in tumors, liposomes can preferentially accumulate in tumor tissues through the increased permeability and retention (EPR) effect.

The ability to actively target: Ligands or antibodies that recognize particular receptor on tumor cells

Release under Control

Curcumin can be engineered into the lipid bilayer of liposomes such that it releases at a certain pace or in response to particular stimuli. With the potential to increase therapy efficacy and decrease administration frequency, this regulated release may help sustain therapeutic concentrations of curcumin for prolonged periods of time.

ADJUNCTIVE TREATMENT

Curcumin and additional medicinal substances can be co-encapsulated using liposomal formulations. This strategy might possibly:

Boost treatment effectiveness overall - Permit synergistic effects between several medicinal agents

Diminish the necessary dosages of specific medications, potentially reducing adverse effects

Liposomal Curcumin Formulation Strategies

Different approaches have been used to maximize liposomal curcumin formulations for the treatment of oral cancer:

Content of Lipids

The qualities of the final liposomes can be greatly influenced by the selection of lipids employed in liposome formulation. In an effort to maximize curcumin encapsulation efficiency, stability, and release kinetics, researchers have experimented with different lipid combinations. For instance, adding cholesterol to the lipid bilayer can improve liposome stability and control drug release [40].

Alterations to the Surface

Liposomes can be surface modified to improve their stability, duration of circulation, and targeting capacity. Among the strategies are:

PEGylation: By lessening identification and clearance by the reticuloendothelial system, coating liposomes with polyethylene glycol (PEG) can lengthen their duration in circulation.

Ligand conjugation: Targeting oral cancer cells can be improved by attaching particular ligands or antibodies to the liposome surface.

Size Optimization

Liposome biodistribution, cellular absorption, and tumor penetration can all be impacted by size. Researchers have experimented with several size ranges to maximize liposomal curcumin's effectiveness in treating oral cancer.

Liposomes Sensitive to pH

To improve the specificity of curcumin delivery to oral cancer cells, pH-sensitive liposomes that release their contents in the slightly acidic tumor microenvironment can be developed.

Liposomes with Multiple Uses

Scholars are presently investigating the creation of multifunctional liposomes that integrate medication delivery with either stimuli-responsive release mechanisms or imaging capabilities.

The development of liposomal curcumin for the treatment of oral cancer has advanced significantly as a result of the adoption of various formulation technologies. The preclinical and clinical trials that assessed these formulations' efficacy are examined in the sections that follow.

PRECLINICAL STUDIES OF LIPOSOMAL CURCUMIN IN ORAL CANCER

Liposomal curcumin's promise in oral cancer models has been the subject of numerous preclinical investigations. These investigations have yielded significant understandings on the effectiveness, mechanisms of action, and possible benefits of this strategy.

Research in Vitro

In vitro investigations on oral cancer cell lines have shown that liposomal curcumin is more effective than free curcumin.

Enhanced Absorption by Cells

According to a study by Wang et al. [41], oral squamous cell carcinoma (OSCC) cells absorbed liposomal curcumin more effectively than free curcumin. Induction of apoptosis and higher cytotoxicity in cancer cells were connected with the improved uptake.

Increased Carcinogenicity

According to Mazzarino et al. [42], at equal doses, liposomal curcumin was more cytotoxic to several OSCC cell lines than free curcumin. The higher cellular absorption and prolonged intracellular release of curcumin were credited with the enhanced impact.

Signaling Pathway Modification

Studies conducted in vitro have demonstrated that liposomal curcumin more successfully alters important signaling pathways linked to the development of oral cancer. For instance, compared to free curcumin, liposomal curcumin more effectively suppressed NF-κB activation and decreased the production of pro-inflammatory cytokines in OSCC cells [43].

Harmonious Outcomes with Traditional Treatments

Liposomal curcumin has been investigated in several research in conjunction with radiation therapy or traditional chemotherapy drugs. Combining liposomal curcumin with cisplatin in OSCC cells, for example, produced synergistic anti-tumor effects as reported by Rao et al. [44], indicating the possibility of combination therapy techniques.

In Vitro Research

More proof of liposomal curcumin's potential for treating oral cancer has come from animal

models:

Better Pharmacokinetic Results

Research conducted on animal models has validated that liposomal curcumin, when taken orally or intravenously, has superior bioavailability and a longer circulation duration in comparison to free curcumin. For instance, in a rat model, Li et al. [45] found that liposomal curcumin had a noticeably longer half-life than free curcumin and that plasma curcumin concentrations had increased threefold.

Inhibition of Tumor Growth

Liposomal curcumin treatment has been shown in several trials employing xenograft models of oral cancer to significantly reduce tumor growth. In a mouse model of OSCC, Zhao et al. [46] demonstrated that liposomal curcumin more successfully inhibited tumor growth than free curcumin did.

Decreased Spread

Liposomal curcumin may help lower metastasis in oral cancer models, according to certain animal studies. For example, liposomal curcumin therapy decreased lymph node metastases in an orthotopic mouse model of OSCC, possibly through blocking factors related to cancer cell invasion and migration (Chen et al., 47).

Studies conducted in vivo that combine liposomal curcumin with traditional chemotherapy drugs have produced encouraging outcomes. In a mouse model of OSCC, Wang et al. [48] showed that the combination of liposomal curcumin and docetaxel led to improved tumor growth inhibition and decreased side effects compared to docetaxel alone.

Topical Application

In terms of local drug delivery and anti-tumor effects, studies investigating topical use of liposomal curcumin formulations in the oral cavity have yielded encouraging findings. A mucoadhesive liposomal curcumin formulation was created by Mazzarino et al. [49] and showed better retention in the oral mucosa as well as increased anti-tumor activity in a hamster model of oral cancer.

Research on Toxicity

Preclinical toxicity investigations have typically demonstrated the good toleability of liposomal curcumin formulations:

Diminished Systemic Harm

In animal models, liposomal encapsulation has been demonstrated to lessen the systemic toxicity linked to large doses of free curcumin. In a rat model, liposomal curcumin showed less hepatotoxicity and nephrotoxicity at equal doses than free curcumin, according to Kunwar et al. [50].

Research has indicated that liposomal curcumin exhibits therapeutic effects at lower dosages when contrasted with free curcumin, which may mitigate the possibility of adverse reactions. This enhanced safety profile is especially crucial for combination medicines or long-term treatment plans.

CLINICAL RESEARCH AND ITS POSSIBLE CAUSES

Although preclinical research has dominated most studies on liposomal curcumin for oral cancer, there is considerable interest in converting these findings into clinical settings. While there aren't many particular clinical trials examining liposomal curcumin in relation to oral cancer, a number of investigations and continuing trials are investigating the compound's potential in different cancer types, which may provide insight into future uses in oral cancer.

Finalized Clinical Research

Despite not being especially focused on oral cancer, a few clinical trials have shed light on liposomal curcumin's possible applications in cancer treatment:

Safety and Pharmacokinetics

Storka et al.'s phase I clinical trial [51] assessed the safety and pharmacokinetics of a liposomal curcumin formulation in participants who were in good health. When compared to traditional curcumin pills, the study found much greater plasma curcumin concentrations. Serious side effects were not noted.

Performance in Other Forms of Cancer

Pastorelli et al.'s phase II trial [52] looked into the effects of liposomal curcumin in patients with advanced colorectal cancer who were receiving standard chemotherapy. Patients getting the combined therapy showed increased progression-free survival and quality of life, according to the study.

Active Clinical Research

Liposomal curcumin is presently being used in a number of clinical trials investigating different cancer types, which may yield important data regarding its possible utility in oral cancer:

Methods of Combination Therapy

The benefits of liposomal curcumin combined with conventional chemotherapy in patients with advanced head and neck squamous cell carcinoma are being studied in a phase II trial (NCT04263506).

Regional Utilization

The effectiveness of a topical liposomal curcumin formulation in treating patients with oral leukoplakia—a precancerous disorder of the oral cavity—is being assessed in an ongoing research (NCT03901976).

Possible Clinical Uses for Oral Cancer

Several possible clinical applications of liposomal curcumin in oral cancer can be imagined based on preclinical findings and ongoing research:

Chemical Resistance

Liposomal curcumin may be utilized in high-risk patients or those with oral precancerous lesions as a chemopreventive measure. Because of its antioxidant and anti-inflammatory

qualities, it is a promising option to stop premalignant lesions from developing into invasive malignancy.

Supplemental Treatment

When liposomal curcumin is combined with conventional treatments like radiation, chemotherapy, or surgery, it may increase the effectiveness of the treatment or lessen its negative effects. Preclinical research has shown that combination techniques may have synergistic effects that could enhance overall treatment outcomes.

Rehabilitative Care

Liposomal curcumin may be used as a maintenance therapy to lower the chance of recurrence following initial treatment. It is a promising option for long-term therapy due to its capacity to alter several signaling pathways implicated in the development of cancer.

Intensive Care

Liposomal curcumin may provide palliative advantages in advanced cancer cases by lowering pain, inflammation, and other symptoms associated with the disease. Due to its superior safety profile, it is a desirable alternative for patients with advanced disease whose quality of life needs to be improved.

Administering Local Treatment

It may be possible to create liposomal curcumin formulations with topical treatments specifically for oral lesions or surgical sites. This strategy might minimize systemic exposure and adverse consequences while optimizing local medication concentrations.

Difficulties and Prospects

Although liposomal curcumin exhibits promise in the treatment of oral cancer, a number of obstacles must be overcome in order to fully fulfill its potential:

Formulation Standardization

Liposomal curcumin formulations can differ greatly in terms of their stability, biological effects, and physicochemical characteristics. For clinical applications to produce consistent results, standardization of production processes and quality control systems is essential.

Delivery Method Optimization

To precisely enhance delivery strategies for oral cancer, more research is required. Creating mucoadhesive liposomal formulations for better retention in the oral cavity is one example of this.

- Investigating cutting-edge delivery methods, like intralesional injection or mixing with oral rinses

Protocols for Dosing and Treatment

Comprehensive clinical evaluation will be necessary to determine the best liposomal curcumin dosage and treatment plans for patients with oral cancer. Carefully evaluating elements such as dosage frequency, treatment length, and combination with other medications is necessary.

Long-term Safety and Efficacy:

Although liposomal curcumin has demonstrated promising safety profiles in preclinical studies and early clinical trials, long-term safety and efficacy data in oral cancer patients remain lacking. To determine the role of liposomal curcumin in the management of oral cancer, well-designed, long-term clinical trials will be necessary.

Although curcumin has a number of suggested mechanisms of action, more research is needed to clarify the precise mechanisms by which liposomal curcumin works in oral cancer. This knowledge could guide the creation of more focused and efficacious formulations

Researching liposomal curcumin's synergistic interactions with other innovative drugs or traditional medicines may result in more potent treatment plans. It will be essential to determine the best combination regimens and comprehend the underlying mechanisms of synergy.

Methods of Personalized Medicine

With breakthroughs in our understanding of the molecular underpinnings of oral cancer, liposomal curcumin may be used to create customized treatment regimens. Finding biomarkers for liposomal curcumin response may aid in individualized patient treatment planning.

Manufacturing and Scale-up Challenges

There are many obstacles in the way of converting liposomal curcumin produced in laboratories to large-scale manufacture for medical application. It will be crucial to create scalable, affordable production techniques that preserve product quality and uniformity if clinical use is to become widely distributed.

3. Discussion

Curcumin, a bioactive compound derived from turmeric, has been extensively studied for its therapeutic potential against various diseases, particularly cancers such as head and neck squamous cell carcinoma (HNSCC). Numerous studies have demonstrated curcumin's multifaceted mechanisms of action, including anti-inflammatory, antioxidant, and anti-proliferative effects. Aggarwal and Harikumar (2009) highlighted its broad therapeutic effects across neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune, and neoplastic diseases, while Wilken et al. (2011) specifically reviewed its anti-cancer properties in HNSCC, noting its ability to inhibit cell proliferation and induce apoptosis. The compound's poor bioavailability, however, has been a significant challenge, as discussed by Anand et al. (2007), leading to the development of various delivery methods such as liposomal curcumin, which Feng et al. (2017) explored for enhanced application in cancer therapy. The potential of curcumin to modulate key signaling pathways, such as NF-κB, is well-documented, with Aggarwal (2004) and Aggarwal and Sung (2009) illustrating its role in cancer cell survival and proliferation. Additionally, the synergistic effects of curcumin with conventional cancer therapies, as shown by Chakravarti et al. (2007) and Lin et al. (2009), underscore its potential as an adjunctive treatment.Table 1 summarizes these studies, providing a comprehensive overview of curcumin's therapeutic promise and the ongoing efforts to overcome its bioavailability issues.

Table 1: Summarizing these studies, providing a comprehensive overview of curcumin's therapeutic promise and the ongoing efforts to overcome its bioavailability issues.

Study	Study Design	Sample Size	Type of Cancer	Dose and Form of Curcumin	Key Findings
Aggarwal & Harikumar (2009)	Review	N/A	Various neoplastic diseases	N/A	Curcumin modulates inflammatory pathways, exhibiting potential therapeutic effects in cancer.
Wilken et al. (2011)	Review	N/A	Head and neck squamous cell carcinoma	N/A	Curcumin induces apoptosis, inhibits proliferation, and reduces metastasis in head and neck squamous cell carcinoma.
Kunnumakkara et al. (2008)	Review	N/A	Various cancers	N/A	Curcumin inhibits proliferation, invasion, angiogenesis, and metastasis by interacting with multiple cell signaling proteins.
Anand et al. (2007)	Review	N/A	Various cancers	N/A	Curcumin has promising anti-cancer properties, but its bioavailability poses a significant challenge.
Feng et al. (2017)	Experimental	In vitro and in vivo studies	Various cancers	Liposomal curcumin	Liposomal curcumin enhances bioavailability and shows promise in cancer therapy.
Lin et al. (2009)	Experimental	In vitro study	Oral cancer cells	Curcumin	Curcumin inhibits invasion and migration of oral cancer cells by inducing apoptosis and reducing MMP-2 production.
Singh & Singh (2009)	Experimental	In vitro study	Cervical carcinoma cells	Curcumin	Curcumin induces cytotoxicity in cervical carcinoma cells through various molecular mechanisms.

4. Conclusion

One method that shows promise for increasing curcumin's therapeutic potential in the treatment of oral cancer is liposomal curcumin. Liposomal formulations provide increased cellular absorption, improved bioavailability, and the possibility of targeted administration to oral cancer tissues by resolving the drawbacks of free curcumin. Significant anti-tumor effects, such as the induction of apoptosis, the suppression of cell proliferation, and the modification of important signaling pathways implicated in the advancement of oral cancer, have been shown in preclinical investigations.

Although liposomal curcumin has not been the subject of many clinical trials especially in oral cancer, ongoing trials in related disease types offer important insights and open the door for potential future applications in oral cancer. Liposomal curcumin has a wide range of possible clinical uses in the treatment of oral cancer, including adjuvant therapy, palliative care, and chemoprevention.

Before liposomal curcumin can be completely realized as a treatment option for patients with oral cancer, there are still a few issues that need to be resolved. These consist of formula standardization, administration mechanism optimization, optimal dosing regimen selection, and assessment of long-term safety and efficacy.

Liposomal curcumin is expected to become more significant in the treatment of oral cancer as research in this area develops. It is a promising option for enhancing treatment outcomes and quality of life for patients with oral cancer due to its distinct combination of anti-cancer activities, excellent safety profile, and potential for synergistic combinations with current supplementation .

To fully realize the potential of liposomal curcumin in the treatment of oral cancer, future research should concentrate on carrying out carefully planned clinical studies, examining novel formulation methodologies, and researching combination approaches. Liposomal curcumin may prove to be a useful tool in the fight against oral cancer with more research and development, giving patients dealing with this difficult illness fresh hope .

References

1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
2. Kashwani R, Sawhney H. Assessing the Sensitivity and Specificity of Toluidine Blue Staining in Oral Cancer Screening Among Inmates: A Prison-Based Study. J. Adv. Zool. [Internet]. 2023 Oct. 10 [cited 2024 Jul. 21];44(S3):450-6. Available from: https://jazindia.com/index.php/jaz/article/view/618
3. Aggarwal, B. B., & Harikumar, K. B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. The international journal of biochemistry & cell biology, 41(1), 40-59.
4. Wilken, R., Veena, M. S., Wang, M. B., & Srivatsan, E. S. (2011). Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.

Molecular cancer, 10(1), 12.
5. Zlotogorski, A., Dayan, A., Dayan, D., Chaushu, G., Salo, T., & Vered, M. (2013). Nutraceuticals as new treatment approaches for oral cancer: II. Green tea extracts and resveratrol. Oral oncology, 49(6), 502-506.
6. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: problems and promises. Molecular pharmaceutics, 4(6), 807-818.
7. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., ... & Nejati-Koshki, K. (2013). Liposome: classification, preparation, and applications. Nanoscale research letters, 8(1), 102.
8. Feng, T., Wei, Y., Lee, R. J., & Zhao, L. (2017). Liposomal curcumin and its application in cancer. International journal of nanomedicine, 12, 6027.
9. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3),
10. 209-249.
11. Elango, J. K., Gangadharan, P., Sumithra, S., & Kuriakose, M. A. (2006). Trends of head and neck cancers in urban and rural India. Asian Pacific Journal of Cancer Prevention, 7(1), 108-112.
12. Hashibe, M., Brennan, P., Benhamou, S., Castellsague, X., Chen, C., Curado, M. P., ... & Zhang, Z. F. (2007). Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Journal of the National Cancer Institute, 99(10), 777-789.
13. Blot, W. J., McLaughlin, J. K., Winn, D. M., Austin, D. F., Greenberg, R. S., Preston-Martin, S., ... & Fraumeni Jr, J. F. (1988). Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Research, 48(11), 3282-3287.
14. Gillison, M. L., D'Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S., & Viscidi, R. (2008). Distinct risk factor profiles for human papillomavirus type 16–positive and human papillomavirus type 16–negative head and neck cancers. Journal of the National Cancer Institute, 100(6), 407-420.
15. Angadi, P. V., & Rekha, K. P. (2011). Oral submucous fibrosis: a clinicopathologic review of 205 cases in Indians. Oral and Maxillofacial Surgery, 15(1), 15-19.
16. Krishnan, S., Swaminathan, S., & Narayanan, R. (2008). Diet and oral, pharyngeal, and esophageal cancer. Indian Journal of Medical Research, 128(5), 605-608.
17. Murthy, V., Bhat, R., & Shenoy, N. (2011). Genetic susceptibility to head and neck squamous cell carcinoma. Cancer Research and Treatment, 43(2), 67-73.
18. Aggarwal, B. B., Sundaram, C., Malani, N., & Ichikawa, H. (2007). Curcumin: the Indian solid gold. Advances in Experimental Medicine and Biology, 595, 1-75.
19. Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883-899.
20. Shishodia, S., Sethi, G., & Aggarwal, B. B. (2005). Curcumin: getting back to the roots. Annals of the New York Academy of Sciences, 1056(1), 206-217.
21. Jurenka, J. S. (2009). Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alternative Medicine Review, 14(2), 141-153.
22. Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010). Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biology and Medicine, 49(11), 1603-1616.
23. Menon, V. P., & Sudheer, A. R. (2007). Antioxidant and anti-inflammatory properties of curcumin. Advances in Experimental Medicine and Biology, 595, 105-125.

24. Krishnaswamy, K. (2008). Chemopreventive agents from dietary sources. In Principles of Molecular Oncology (pp. 387-398). Humana Press.
25. Kunnumakkara, A. B., Anand, P., & Aggarwal, B. B. (2008). Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Letters, 269(2), 199-225.
26. Aggarwal, B. B. (2004). Nuclear factor-kappaB: the enemy within. Cancer Cell, 6(3), 203-208.
27. Aggarwal, B. B., & Sung, B. (2009). NF-κB in cancer: a matter of life and death. Cancer Discovery, 1(6), 92-101.
28. Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007). MAP kinase signalling pathways in cancer. Oncogene, 26(22), 3279-3290.
29. Wilken, R., Veena, M. S., Wang, M. B., & Srivatsan, E. S. (2011). Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Molecular Cancer, 10, 12.
30. Ravindran, J., Prasad, S., & Aggarwal, B. B. (2009). Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? The AAPS Journal, 11, 495-510.
31. Chakravarti, N., Myers, J. N., Aggarwal, B. B., & Natarajan, K. (2007). Targeting constitutively active nuclear factor-κB and its down-regulation by curcumin (diferuloylmethane) potentiates the effect of cisplatin in human head and neck squamous cell carcinoma. Molecular Cancer Therapeutics, 6(4), 1198-1208.
32. Wang, Z., Zhang, Y., Banerjee, S., Li, Y., Rahman, K. M., & Sarkar, F. H. (2006). Modulation of EGFR-related protein kinases and downregulation of nuclear factor-κB signal transduction pathway by 3,3′-diindolylmethane inhibit invasion and angiogenesis of breast cancer cells. Cancer Research, 66(2), 1117-1124.
33. Lin, S. S., Lai, K. C., Hsu, S. C., Yang, J. S., Kuo, C. L., Lin, J. P., ... & Chung, J. G. (2009). Curcumin inhibits the invasion and migration of human oral cancer cells by inducing apoptosis and reducing matrix metalloproteinase-2 production. Food and Chemical Toxicology, 47(1), 286-292.
34. Singh, M., & Singh, N. (2009). Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Molecular and Cellular Biochemistry, 325(1-2), 107-119.
35. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics, 4(6), 807-818.
36. Chiba, T., Marusawa, H., & Ushijima, T. (2012). Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology, 143(3), 550-563.
37. Anand, P., Thomas, S. G., Kunnumakkara, A. B., Sundaram, C., Harikumar, K. B., Sung, B., ... & Aggarwal, B. B. (2008). Biological activities of curcumin and its analogs (Congeners) made by man and Mother Nature. Biochemical Pharmacology, 76(11), 1590-1611.
38. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., ... & Nejati-Koshki, K. (2013). Liposome: classification, preparation, and applications. Nanoscale Research Letters, 8(1), 102.
39. Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A., & Maitra, A. (2007). Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. Journal of Nanobiotechnology, 5, 3.
40. Maeda, H., Nakamura, H., & Fang, J. (2013). The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Advanced Drug Delivery Reviews, 65(1), 71-79.